As for its role in DNA damage response, independent studies have shown that SLFN11 augments the sensitivity of cancer cells to a wide range of DNA-damaging agents including platinum-derivatives, topoisomerase inhibitors, PARP inhibitors and replication inhibitors [4–6, 13–16]. Here, SLFN11 is linked to cancer.